HumanCell

HumanCell is a South Korean biotechnology company focused on the development of next-generation cell therapies for oncology and degenerative diseases. The company leverages a proprietary platform for the high-efficiency expansion and activation of natural killer (NK) cells and mesenchymal stem cells (MSCs). Its primary research efforts are directed toward overcoming the challenges of treating solid tumors and providing regenerative solutions for autoimmune conditions. HumanCell's lead pipeline candidates, including HC-NK01, aim to deliver enhanced therapeutic efficacy through improved cell persistence and tumor-targeting capabilities. The company is positioned as an innovator in the rapidly evolving field of adoptive immunotherapy.